Advertisement

Biophysics Reports

, Volume 4, Issue 5, pp 233–242 | Cite as

Animal protein toxins: origins and therapeutic applications

  • Na Chen
  • Siqi Xu
  • Yuhan Zhang
  • Feng Wang
Open Access
Review
  • 158 Downloads

Abstract

Venomous animals on the earth have been found to be valuable resources for the development of therapeutics. Enzymatic and non-enzymatic proteins and peptides are the major components of animal venoms, many of which can target various ion channels, receptors, and membrane transporters. Compared to traditional small molecule drugs, natural proteins and peptides exhibit higher specificity and potency to their targets. In this review, we summarize the varieties and characteristics of toxins from a few representative venomous animals, and describe the components and applications of animal toxins as potential drug candidates in the treatment of human diseases, including cancer, neurodegenerative diseases, cardiovascular diseases, neuropathic pain, as well as autoimmune diseases. In the meantime, there are many obstacles to translate new toxin discovery to their clinical applications. The challenges, strategies, and perspectives in the development of the protein toxin-based drugs are discussed as well.

Keywords

Animal venoms Protein and peptides Targets Human diseases Clinical applications 

INTRODUCTION

Animal venoms are composed of varieties of proteins and peptides fine-tuned by millions of years of evolution. These toxins target multiple ion channels, receptors, and enzymes with high potency and sometimes exquisite selectivity, therefore, attracting much attention to further investigate their pharmacological and physiological properties. Toxins synthesized by venomous animals from both terrestrial animals and marine animals, such as scorpions, snakes, spiders, bees, cone snails, and sea anemones, are injected into the body for hunt or defense by animal wounding apparatus, such as fangs, barbs, spines, and stingers. Some venomous animals have been used to treat diseases for millennia in many parts of the world. Scorpion, as an example, has been used to treat spasms and endogenous wind in traditional Chinese medicine. Many important effects have been discovered when studying the functionality of animal toxins. The high selectivity and potency make animal toxins as brilliant pharmacological tools and drug candidates. Proteins and peptides are the main active components in animal venoms (Fig. 1), which mostly contain multiple disulfide bonds. The numbers of disulfide bonds vary in different venomous species, such as 10–40 cysteine residues have been found in cone snails, 40–80 residues in scorpions and snakes, with remarkable structural diversities resulted from long-term selective pressure and coevolution process. Although protein toxins show multiple advantages compared to small molecule drugs for therapeutic applications, such as higher potency and selectivity, they still face many challenges, such as the short circulating half-life, the lack of membrane permeability, and poor oral bioavailability as well. In this paper, we reviewed the resources of venomous animals, the representative components of their venoms, and the applications in treatment of human diseases. Finally, we discussed the challenges and opportunities of the drugs derived from natural animal toxins.
Fig. 1

Comparison of the numbers of unique peptides in different venomous animals and the presentation of promising drug candidates identified from their venoms

THE SOURCES OF ANIMAL VENOMS

Here, we only describe the popular toxins from Kingdom Animalia. The composition of venoms depends on the species. In many cases, a small dose of them can lead to painful disorders or even death. The common and well-known venomous animals include genus Conus (cone snails), arthropods (spiders, scorpions, centipedes, bees, etc.), vertebrates (snakes, lizards, etc.), and cnidarians (jellyfishes, sea anemones, etc.) as well.

Venoms from genus conus (cone snails)

The Conoidea superfamily (cone snails, etc.) is an extremely diverse group of predatory marine neogastropoda divided into 16 families, among which, the cone snails are the most extensively studied. The toxins produced by venomous snails are mostly bioactive peptides targeting the ion channels or receptors in the nervous systems. They are generally 10–30 amino acids in length and rarely more than 60, with high specificity and affinity to their targets. More than 80,000 conotoxins so far have been found in various cone snails all over the world. Cone snail toxins named as conotoxins or conopeptides are generally classified by three major criteria. We categorized the toxins in Fig. 2 according to Akondi’s work (2014). Various conotoxins are the natural ligands to many ion channels including Na+ channel, K+ channel and Ca2+ channel, receptors, such as nicotinic acetylcholine receptor, serotonin receptor, and transporters. ω-MVIIA (ziconotide), approved by the U.S. Food and Drug Administration (FDA), is the most famous product derived from cone snail venom, which displays remarkable analgesic activity in treating chronic pain via its potent inhibitory effect on N-type Ca2+ channels (Rigo et al. 2013; Sahand et al. 2016).
Fig. 2

An example of the classification of disulfide-rich conotoxins modified from Akondi’s work (2014). Based on the homology of their conserved signal sequence, cysteine frameworks, as well as the targets, conotoxins can be classified into numbers of superfamilies and families. NE: norepinephrine; nAChR: nicotinic acetylcholine receptor

Venoms of snakes

More than 200 species of venomous snakes exist in the world. Four major venomous snake families include Hydrophiae, Elapidae, Viperidae, and Crotalidae (Matsui et al. 2000). Snake venom is the combination of proteins, peptides, inorganic ions, and so on, with specific chemical and biologic activities. Meanwhile, it seemed that the relatively common and similar components of venoms are produced by the same family of snakes, but they are basically different depending on each snake species (Ouyang et al. 1990; Tu 1996). For example, many neurotoxins and dendrotoxins have been found dominantly in Elapids and Hydrophids, while myotoxins and hemorrhagic toxins are frequently discovered in venoms of Crotalidae and Viperidae. As neurotoxins, cytotoxins, cardiotoxins, nerve growth factors, various enzymes (e.g., proteases, phospholipases), enzyme inhibitors, etc., some components of snake venoms can be used as pharmacological or diagnostic tools, and even drugs to treat cancer, chronic pain, neuromuscular disorders, autoimmune diseases, and blood and cardiovascular disorders. (Calderon et al. 2014; Pal et al. 2002; Wang and Qin 2018).

Venoms of scorpions

There are thirteen families and about 1750 scorpion species in the world. Generally, the smaller scorpion species with slender claws have more toxic venoms. Scorpion venom is a mixture of compounds containing salts, nucleotides, biogenic amines, enzymes such as phospholipase, hyaluronidase, L-amino acid oxidase, metalloproteinase, serine protease, mucoproteins, as well as small peptides. Some of these venoms have been well studied, laying foundation for further drug development effort in the pharmaceutical industry. For example, components of scorpion venoms possess anticancer activities. The anticancer effects are achieved mainly via regulating the expression of ion channels, e.g., Cl channels, K+ channels, and Na+ channels, inhibiting cell proliferation or inducing apoptotic activities by modulation of cell cycle or activation of caspase-dependent apoptosis pathways (Cohen-Inbar and Zaaroor 2016; Ding et al. 2014a; Wang and Guo 2015). Furthermore, the components of scorpion toxin have antimicrobial activities. Three types of antimicrobial peptides have been identified according to the structural homology. The details of biological activities and mechanism of actions of the antimicrobial peptides from scorpion venoms have been well studied and reviewed by Harrison et al. (2014).

Venoms of spiders

Spiders are the overwhelming majority of venomous animals on the planet. The number of spider species is predicted to be about 150,000, which is perhaps greater than the total numbers of all other venomous creatures. Yet, we only have limited knowledge on spider species and their venoms. Spider venoms are complex containing active peptides proteins, and low molecular mass compounds, which target a large group of receptors, ion channels, and enzymes. Most of known disulfide-rich peptides and proteins isolated from spider venoms usually target to excitable cell membranes, primarily modulating the functions of ion channels (Ca2+, Na+, and K+), membrane receptors, and so on. So far, only a small number of the spider venoms have been identified and pharmacologically characterized, but their biological activities are potent and impressive. Spider toxin peptides exert many biological functions containing neuroprotective effect (Chassagnon et al. 2017), antimicrobial activity (Samy et al. 2017), analgesic effect (Deuis et al. 2017), enzyme inhibitory activities, etc. For instance, ASIC1a, a subunit of acid sensing ion channels (ASICs) is a novel therapeutic target for many pathophysiological diseases, such as ischemia, pain, neurodegenerative diseases, autoimmune disorders, and mental diseases. (Chen and Wang 2016; Deval and Lingueglia 2015; Wang et al. 2016b; Zeng et al. 2014). So far, the only potent and specific inhibitor of ASIC1a is π-TRTX-Pc1a, a 40-residue peptide isolated from spider venom (Cristofori-Armstrong and Rash 2017).

Venoms of centipedes

Centipedes are one of the oldest extant venomous predators on the planet, and there are about 3500 species all over the world. Centipedes have been used as traditional Chinese medicinal animal for hundreds of years to treat many disorders including children’s convulsions, hemiplegia, epilepsy, cough, scrofula, tuberculosis, cardiovascular diseases, and so on. It was also found that the decoction of centipedes has anti-inflammatory effects and analgesic activities. Unlike scorpions and spiders, relatively less attention was drawn to centipede venoms due to their small body size and low venom yields in the past. Recently, lots of studies indicate that the components of centipedes are composed of many antimicrobial peptides, cytotoxic enzymes, ion channel modulators, protease, and neurotoxin peptides as well (Hakim et al. 2015), which could provide valuable resource for drug discovery. For instance, components from Chinese red-headed centipedes, S. subspinipes mutilans, have been identified as modulators of voltage-gated ion channels (Yang et al. 2012, 2013), which makes centipedes venoms as potential drug candidates for pain and other channelopathy. Another novel peptide, colopendin 1, was also isolated from S. subspinipes mutilans, which showed potent antimicrobial activity with minimal side effects (Choi et al. 2014). Subsequently, more than 17 novel antimicrobial peptides have been found from S. subspinipes mutilans. Their antimicrobial activities have been evaluated by in vitro and/or in vivo models. Among them, ten synthetic peptides were identified for their potent antimicrobial activities with no toxic effect to erythrocytes in mouse model (Fratini et al. 2017), which makes them valid alternatives to traditional small molecular weight antibiotics.

THE THERAPEUTIC APPLICATIONS OF ANIMAL TOXINS IN DISEASES

Animal venoms are complex mixtures. Some components in mixtures can potently and selectively act on the protein targets and show pharmacological effects to relevant human diseases and disorders. The components of venoms from various species have been analyzed in many studies. The toxins across the species often have low sequence homology, and different structural characteristics. Interestingly, some toxin peptides or proteins from different species act on the same target, but the effects of those toxins may be different dependent on their specificities and inhibitory activities toward the target proteins. Those toxins with high specificity, high potency, and proper inhibitory activity are the basis of drug design. In following paragraphs, toxins with reported activities or applications in various diseases are discussed.

Anticancer activity

Cancer is a disease induced by some reasons including genetically or environmentally caused mutations, infections with pathogens, bad living habits, drug abuse, etc., leading to uncontrolled division of abnormal cells in a part of the body, which directly affects human living quality and even life. Many treatments have been adopted to prevent the growth of cancerous cells or to remove precancerous tissue that may turn into cancer. Surgery procedures are usually used together with the treatment of chemotherapy and/or radiation therapy. The chemotherapy is based on the administration of small molecular weight chemicals to kill cancerous cells, commonly lacking of target specificity, taking more risks of undesired side effects, such as bone marrow toxicity, cardiotoxicity, and immunosuppression leading to enhanced risks of infection. Antitumor drug development based on natural animal venoms has become one of the new strategies to handle these problems.

In general, toxins from natural resources exhibit potent cytotoxic activity to cancerous cells via modulation of the apoptosis response pathway, impairment of cancer proliferation, inhibition of enzymatic activities, or alteration of the cell cycle. Among those, snake venoms are rich source of cytotoxins for oncological studies. Cytotoxins (CT1, CT2, and CT3), lectins, metalloproteinases, aggretin, disintegrins, and rhodostomin are components identified from different type of snake venoms, some of them have been verified the validity on the treatment of various human cancers (Macedo et al. 2015; Calderon et al. 2014; Jain and Kumar 2012; Vyas et al. 2013).

It was found that altered or abnormal expression of ion channels on the surface of cells are involved in cancer processes and pathology. Therefore, the animal venoms targeting ion channels (including Na+, K+, Ca2+, and Cl) may have selective activities against cancer cells. Anticancer effects of animal venoms have been studied cross several species, including bee, scorpion, spiders, and so on, targeting ion channels in different cancer types. For example, AGAP peptide from BmK scorpion venom acting as the selective inhibitor of a voltage-gated sodium channel was verified to have antitumor activity due to its role in the impairment of cell cycle and interfering with factors essential for modulating signaling pathways relevant to cell survival and growth, apoptosis, cell proliferation, and so on (Zhao et al. 2011). Chlorotoxin and other scorpion toxins associated with ion channels also have anticancer potentialities (Ding et al. 2014b). Moreover, venom components from other animal species, like family Bufonidae, bees, and spiders, are also found antitumor activities (Mahadevappa et al. 2017; Oršolić 2012; Rodriguez et al. 2017).

Animal venoms for the treatment of neurodegenerative diseases

Neurodegeneration is the progressive disease resulting in the loss of structures or functions, and the final lethal destiny of neurons. Neurodegenerative diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, etc., affect millions of individuals worldwide. So far, such diseases are incurable and there is no particularly effective drug available for treatment, making an urgent need for effective drugs exploring. Neurodegeneration can be triggered by genetic mutation, protein misfolding, oxidative stress, mitochondrial damage, neuro-inflammation, glutamatergic excitotoxicity, aging, aggregate formation, and apoptosis. Because humans have been part of the long-term coevolution process together with prey and predator animals, some animal venom components exhibit excellent selectivity and affinity for various targets located in human central nervous systems. Recent research indicates that animal venoms are rich in neuroactive molecules, which can be pharmacological drug tools to analyze the pathological progress of neurodegenerative disorders and provide good candidates for new drug development. For instance, snake venoms rich in neuroactive components have been widely studied for its potential therapeutic applications in neurodegenerative disorders, such as AD. The dendrotoxins extracted from the venom of the African mambas (Dendroaspis genus) could block K+ channel, and increase acetylcholine release, therefore, useful to treat AD induced by acetylcholine deficits. Metalloproteases from snake venom can degrade the amyloid β-protein (Aβ), one of the components of amyloid plaques, in an animal AD model. (Nalivaeva et al. 2012). Bee venom from Apis mellifera possesses the anti-inflammatory effect, and can reduce microglial activation, CD4+ T cells infiltration, and oxidative stress as well as improve motor coordination and balance in various animal Parkinson’s models (Awad et al. 2017; de Souza et al. 2018; Silva et al. 2015).

Analgesic activity

Neuropathic pain is a chronic pain disease, caused by neuron damages or firing aberrantly (Hamad et al. 2018). During the process of pain signaling delivery in neurons, postsynaptic neurons are activated or inhibited by excitatory or inhibitory neurotransmitters released from presynaptic neurons, respectively (Fig. 3). Many channels and transporters contribute to the neurotransmitter release or Ca2+ fluxes, and they are the targets of toxins, which are allowed to modulate the neuron signaling delivery. Among them, toxins having high specificity and selectivity on the targets can be used as drug candidates. For example, ω-conotoxin MVII A (25 amino acids) from Cone snail is the blocker of N-type CaV2.2 voltage-gated calcium channel (VGCC) (Adams and Berecki 2013), which is located on central terminals of primary sensory dorsal root ganglion (DRG) neurons (nociceptors) in spinal cord (Cizkova et al. 2002). The blockage of CaV2.2 channel in presynaptic neurons inhibits the action potential formation in the secondary pain sensory neuron and stops the pain signaling delivery. Because of the high potency of ω-conotoxin MVII A, its synthetic version (ziconotide) has been applied to treat neuropathic pain as a medicine called Prialt. Also, the Chi-conotoxin MrIA, isolated from Conus marmoreus, is a noncompetitive inhibitor of the norepinephrine transporter (NET) on a terminal of brain stem descending axons. The blockage of NET in presynaptic membrane by Chi-conotoxin MrIA stops the reuptake of neurotransmitter noradrenaline, hence increasing the volume of noradrenaline in the synaptic cleft. Noradrenaline, a transmitter released from descending axon terminals, can block the propagation of pain signals by two different ways, (1) inhibition of the activity of spinal relay neurons by hyperpolarizing cell membrane potentials (a postsynaptic inhibition); (2) suppression of the terminal activities of nociceptive primary afferent fibers through volume transmission of noradrenaline (a presynaptic inhibition), therefore preventing the generation of action potential and blocking the ascending pain signals (Pertovaara and Almeida 2006). Toxin-derived drugs for the treatment of neuropathic pain are usually tested in vivo by using mouse allodynia model (Nielsen et al. 2005) and hypersensitivity (Obata et al. 2005) behavioral assays. The synthetic version of Chi-conotoxin MrIA, Xen2174 (13 amino acids) (Sharpe et al. 2003), has been tested in clinical phase II for the treatment of neuropathic pain.
Fig. 3

Descending pain-inhibitory systems in spinal cord. Diagrams A and B illustrate two different ways for brain stem descending axons to inhibit pain signaling from nociceptive primary afferent nerve fibers in spinal cord. A Direct postsynaptic inhibition of pain signaling. B Indirect presynaptic inhibition of pain signaling via volume transmission of an inhibitory neurotransmitter released from brain stem descending inhibitory axons

Cardiovascular diseases

Cardiovascular disease is a class of diseases that involve the heart and blood vessels, such as hypertensive heart disease, heart failure, stroke, thromboembolic disease, and so on. There are several examples of venom-based drugs for the successful treatment of cardiovascular diseases. Bradykinin-potentiating peptide b (BPPb), which is from the Cantil snake venom, is a well-known toxin for the decrease of blood pressure, where the toxin targets an enzyme on tissue surfaces, and is the blocker of human angiotensin-l converting enzyme (ACE). According to renin-angiotensin systems, ACE located on the external surface of endothelial cells of lungs and kidneys is the essential enzyme for generating angiotensin II (AngII), therefore leading to the increase of blood pressure (Masuyer et al. 2012). The enzyme ACE also carries out the effect on cleavage of bradykinin which is a vasodilator for decreasing the blood pressure. Thus, the inhibited ACE fails to produce AngII (a vasoconstrictor) and cleave bradykinin, finally resulting in the decrease of blood pressure. Capoten (captopril), the small molecule drug designed according to structure–activity studies of BPPs, has been widely used for the treatment of hypertension. However, this medicine could have many side effects caused by the free thiol group in the captopril molecular structure. Hence, optimized structural forms of peptide BPPs would improve the treatment of hypertension with reduced side effects.

Venoms are also found to be useful antithrombotics. Thrombosis is the obstruction of the blood vessels through the circulatory system due to the blood clot formation inside the vessels. A key event of thrombus formation is platelet aggregation (Scarborough et al. 1991). Platelets aggregate and adhere to collagen in the sub-endothelial layer of blood vessels through the binding of its receptors (e.g., integrins) with adhesive proteins, such as fibrinogen and von Willebrand factor (VWF). Platelets are then triggered by the binding of collagen, leading to downstream kinase cascades and intra-platelet signaling. In the meantime, the platelet receptor glycoprotein (GP)IIb-IIIa, which is a member of a superfamily of integrins (Scarborough et al. 1991), is converted to their active form to initiate platelet aggregation. The peptide barbourin, from the venom of the southeastern pigmy rattlesnake, Sistrurus m. barbouri, is identified to specifically inhibit the binding of adhesive proteins on the integrin GPIIb-IIIa during the receptor-mediated platelet aggregation (Scarborough et al. 1991), therefore the peptide barbourin is termed “disintegrin.” There are other venom peptides, such as tergeminin, echistatin, and eristicophin, working as “disintegrin” to inhibit the binding of adhesive proteins to integrins (Scarborough et al. 1991). Researchers are convinced that the inhibitory function of disintegrins to platelet aggregation attributes to their anti-thrombotic effects (Lewis and Garcia 2003).

Autoimmune diseases

Autoimmune disease is an abnormal condition arising from an abnormal immune response to a normal body part. Medications acting on the target with selectivity, specificity, and less side effects are needed. Previous studies found that in the process of T lymphocyte immune response, the voltage-gated potassium channel KV1.3 together with calcium-activated K+ channel (KCa) contribute to the membrane potential and calcium signaling in T cells (Shen et al. 2017). The up-regulated expression of KV1.3 in T and B lymphocytes is observed during the development of autoimmune diseases (Wang et al. 2016a). Some toxins from scorpion venoms and sea anemone venoms are found to have the inhibitory functions on KV1.3 channel, which results in the deactivation of effector memory T (TEM) and the secretion of related cytokines, therefore reducing the symptoms of autoimmune diseases. Although many toxins can block KV1.3 channel, such as ShK, BmKTX, OSK1, HsTX1, and so on (Shen et al. 2017), only a few toxins can be utilized as therapeutics for autoimmune diseases according to their potencies, specificities, and inhibitory activities (Kd and IC50, EC50) to this channel. The synthetic version of toxin ShK (ShK-186) (Wang et al. 2016a), produced with an unnatural amino acid, obtains improved specificity to KV1.3 channel and has been applied in clinical phase II (Shen et al. 2017). Apart from the improvement of toxins through synthetic versions, many studies focus on toxin-antibody fusion proteins as therapeutics. One previous study claimed that toxin Vm24 fused in CDR loop of an antibody presents excellent potency, specificity, and inhibitory activity (Wang et al. 2016a). Overall, animal toxins have brilliant prospective on the research and development of therapeutics in various diseases.

CHALLENGES AND OPPORTUNITIES OF ANIMAL PROTEIN- AND PEPTIDE-BASED DRUGS

Most of the peptides and proteins from animal venom are natural ligands of membrane ion channels or receptors with exquisite specificity and high potency, thereby driving many interests to drug exploring. However, native peptides and proteins as drugs are still confronted with many challenges from discovery to clinical application. Firstly, it is highly difficult to isolate or study a single component of peptide or protein in a certain amount from extremely limited supplies of venom. Secondly, most of the toxin peptides are rich in disulfide bonds, the gene engineering and chemical synthesis remain expensive and uncertain to yield enough bioactive products with desired disulfide bridge, since the primary, secondary, and final tertiary structures of proteins and peptides are crucial to their specificity and functionality. Thirdly, the short serum half-lives of many bioactive proteins and peptides limit their final efficacy to their targets in the treatment of diseases. In summary, the advantages and disadvantages are listed in Table 1.
Table 1

The advantages and disadvantages of natural peptides acting as drugs

Advantages

Disadvantages

High activity

Conformational instability during storage and transportation

High specificity

Potential immunogenicity

Low toxicity

Poor oral bioavailability

Broad targets

Short serum half-life

High biological diversity

Low membrane permeability

 

Poor solubility

The development of biotechnology methods enabled production of large quantities of bioactive proteins and peptides that are derived from components of animal venoms at a lower cost and in a relatively easier manner. Several strategies have been developed to extend half-life and reduce immunogenicity of the therapeutic proteins and peptides. These strategies include genetic manipulation of amino acids relevant to stability and/or immunogenicity, genetic fusion to proteins or protein domains, such as immunoglobulin, human serum albumin (HSA), antibody FC domain, as well as chemical conjugation to synthetic polymers, such as PEG. In addition, the development of new drug-delivery systems and new drug forms, such as microspheres, liposomes, and nano- or micro-particles, are also technological options to optimize pharmacological profiles of protein- and peptide-based drugs. Since the first description of a CD4-Fc fusion protein in 1989 (Capon et al. 1989), this class of engineered proteins has been widely adopted (Fig. 4). For instance, the scorpion toxins OsK1 and OdK2 have been successfully fused with antibody FC domain or human serum albumin without reduction of KV1.3-blocking activity (Edwards et al. 2014). While the counteraction of peptide-Fc fusions includes unexpected inflammatory responses, the reduction of biological activity, aggregations of some proteins, and so on. Human serum albumin is another widely used fusion protein vehicle. Compared to Fc fusion, recombinant HAS are technically easier and more efficient, but in most cases the specific activity of HSA-fused toxins has been affected by the presence of the albumin moiety. Chemical conjugation of small proteins and peptides with PEG extends the plasma half-life through increasing the hydrodynamic radius of a protein or peptides, but the PEGylation may reduce the affinity of peptides to its targets in some cases, e.g., PEGylation of an analog of Shk prolonged the plasma half-life dramatically, but decreased the affinity for KV1.3 (Murray et al. 2015). Furthermore, PEG is non-biodegradable, which may limit its usage in the development of protein- and peptide-based drugs.
Fig. 4

Toxin peptides of interest and toxin peptide–antibody fusion. A Toxin peptides of interest. B Toxin peptides–antibody fusion. Four patterns of fusion are illustrated: toxin–(Fab)Ab, toxin–(Fc)Ab, toxin–Fc, and toxin–Fab

Peptide toxins usually contain multiple disulfide bonds which are essential for the structural stability and bioactivity. Although, a combination of technologies has been employed to form the desired disulfide bridges, generating peptides with multiple disulfides are still a great challenge. We recently reported that the structure of BLV1H12, a bovine antibody, has an ultralong heavy-chain complementary determining region, CDR3H, which folds into a unique structural motif. The solvent anti-parallel β-strand stalk and the cross-link knob domain afford a unique “stalk-knob” structure, which was successfully used to graft a number of proteins and peptides to generate stable and potent functional bovine antibody-CDR3H fusions (Liu et al. 2014; Zhang et al. 2013a, b, 2014). Furthermore, Vm24, a natural immunosuppressive peptide collected from Mexican scorpion with high specificity to Kv1.3 channel, was grafted into the CDR regions of the humanized BVK and Synagis (Syn) antibodies by using β-sheet and coiled-coil linkers, respectively. The fusion protein Syn-Vm24-CDR3L exhibited excellent selectivity and potency to human effector memory T cells. The fusion antibody also demonstrated highly improved plasma half-life and stability in rats compared to the parent Vm24 peptide. The efficacy of the fusion protein was then tested in the rat delayed-type hypersensitivity (DTH) model. As expected, a significant suppressing effect has been detected. (Wang et al. 2016a). Moreover, fusion-site optimization and pharmacophore modification could be performed in these peptide-fusion antibodies to further increase the affinity, selectivity, and inhibitory activity to KV1.3 channel. Based on this new type of antibody skeleton, each natural protein and peptide from animal venom can be converted to a recombinant antibody with one or more functionalities, which may hold great promise for the development of new natural protein- and peptide-based drugs.

PERSPECTIVES FOR THE FUTURE

As reported, the market of protein- and peptide-based drugs is growing up to $40 billion per year, or approximate 10% of the total ethical pharmaceutical market. Undoubtedly, we can imagine the number of peptides identified and clinical applications will continue to grow up quickly in future. The innovations for improving the pharmacological profile of protein/peptide-based drugs, such as new fusion approaches, novel chemical synthesis methods, new invention of drug-delivery systems, will become prevalent. Obviously, some key technical hurdles still need to be conquered for the development of effective protein- and peptide-based therapies, such as improvement of the membrane permeability and biological barriers transportation for the therapeutic proteins and peptides. Furthermore, having clear knowledge of therapeutic needs, the relevance of bioactive proteins and/or peptides to their membrane targets and the interaction between them is indispensable for the drug discovery and development. Finally, the rational design of natural protein- and peptide-based drugs with biological methods or in silico tools should be reinforced to accelerate the efficiency of screening and optimizing process.

Notes

Acknowledgements

This work was supported by the grants from National Key R&D Program of China (2017YFA0505400), Strategic Priority Research Program of CAS (XDPB0304), and CAS Pioneer Hundred Talents Program.

Compliance with Ethical Standards

Conflict of interest

Na Chen, Siqi Xu, Yuhan Zhang, and Feng Wang declare that they have no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. Adams DJ, Berecki G (2013) Mechanisms of conotoxin inhibition of N-type (Ca(v)2.2) calcium channels. Biochim Biophys Acta 1828:1619–1628CrossRefGoogle Scholar
  2. Akondi KB, Muttenthaler M, Dutertre S, Kaas Q, Craik DJ, Lewis RJ, Alewood PF (2014) Discovery, synthesis, and structure-activity relationships of conotoxins. Chem Rev 114:5815–5847CrossRefGoogle Scholar
  3. Awad K, Abushouk AI, AbdelKarim AH, Mohammed M, Negida A, Shalash AS (2017) Bee venom for the treatment of Parkinson’s disease: how far is it possible? Biomed Pharmacother 91:295–302CrossRefGoogle Scholar
  4. Calderon LA, Sobrinho JC, Zaqueo KD, de Moura AA, Grabner AN, Mazzi MV, Marcussi S, Nomizo A, Fernandes CF, Zuliani JP, Carvalho BM, da Silva SL, Stábeli RG, Soares AM (2014) Antitumoral activity of snake venom proteins: new trends in cancer therapy. Biomed Res Int 2014:203639CrossRefGoogle Scholar
  5. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, Broder S, Smith DH (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525–531CrossRefGoogle Scholar
  6. Chassagnon IR, McCarthy CA, Chin YK-Y, Pineda SS, Keramidas A, Mobli M, Pham V, De Silva TM, Lynch JW, Widdop RE, Rash LD, King GF (2017) Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a. Proc Natl Acad Sci 114(14):3750–3755CrossRefGoogle Scholar
  7. Chen X, Wang K (2016) The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015. Acta Pharm Sin B 6:522–530CrossRefGoogle Scholar
  8. Choi H, Hwang JS, Lee DG (2014) Identification of a novel antimicrobial peptide, scolopendin 1, derived from centipede Scolopendra subspinipes mutilans and its antifungal mechanism. Insect Mol Biol 23:788–799CrossRefGoogle Scholar
  9. Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, Orendacova J, Yaksh TL (2002) Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp Brain Res 147:456–463CrossRefGoogle Scholar
  10. Cohen-Inbar O, Zaaroor M (2016) Glioblastoma multiforme targeted therapy: the Chlorotoxin story. J Clin Neurosci 33:52–58CrossRefGoogle Scholar
  11. Cristofori-Armstrong B, Rash LD (2017) Acid-sensing ion channel (ASIC) structure and function: insights from spider, snake and sea anemone venoms. Neuropharmacology 127:173–184CrossRefGoogle Scholar
  12. de Souza JM, Goncalves BDC, Gomez MV, Vieira LB, Ribeiro FM (2018) Animal toxins as therapeutic tools to treat neurodegenerative diseases. Front Pharmacol 9:145CrossRefGoogle Scholar
  13. Deuis JR, Dekan Z, Wingerd JS, Smith JJ, Munasinghe NR, Bhola RF, Imlach WL, Herzig V, Armstrong DA, Rosengren KJ, Bosmans F, Waxman SG, Dib-Hajj SD, Escoubas P, Minett MS, Christie MJ, King GF, Alewood PF, Lewis RJ, Wood JN, Vetter I (2017) Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a. Sci Rep 7:40883CrossRefGoogle Scholar
  14. Deval E, Lingueglia E (2015) Acid-sensing ion channels and nociception in the peripheral and central nervous systems. Neuropharmacology 94:49–57CrossRefGoogle Scholar
  15. Ding J, Chua P-J, Bay B-H, Gopalakrishnakone P (2014a) Scorpion venoms as a potential source of novel cancer therapeutic compounds. Exp Biol Med 239:387–393CrossRefGoogle Scholar
  16. Ding J, Chua PJ, Bay BH, Gopalakrishnakone P (2014b) Scorpion venoms as a potential source of novel cancer therapeutic compounds. Exp Biol Med (Maywood) 239:387–393CrossRefGoogle Scholar
  17. Edwards W, Fung-Leung WP, Huang C, Chi E, Wu N, Liu Y, Maher MP, Bonesteel R, Connor J, Fellows R, Garcia E, Lee J, Lu L, Ngo K, Scott B, Zhou H, Swanson RV, Wickenden AD (2014) Targeting the ion channel KV1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life. J Biol Chem 289:22704–22714CrossRefGoogle Scholar
  18. Fratini F, Cilia G, Turchi B, Felicioli A (2017) Insects, arachnids and centipedes venom: a powerful weapon against bacteria. A literature review. Toxicon 130:91–103CrossRefGoogle Scholar
  19. Hakim MA, Yang SL, Lai R (2015) Centipede venoms and their components: resources for potential therapeutic applications. Toxins 7:4832–4851CrossRefGoogle Scholar
  20. Hamad MK, He K, Abdulrazeq HF, Mustafa AM, Luceri R, Kamal N, Ali M, Nakhla J, Herzallah MM, Mammis A (2018) Potential uses of isolated toxin peptides in neuropathic pain relief: a literature review. World Neurosurg 113(333–347):e335Google Scholar
  21. Harrison PL, Abdel-Rahman MA, Miller K, Strong PN (2014) Antimicrobial peptides from scorpion venoms. Toxicon 88:115–137CrossRefGoogle Scholar
  22. Jain D, Kumar S (2012) Snake venom: a potent anticancer agent. Asian Pac J Cancer Prev 13:4855–4860CrossRefGoogle Scholar
  23. Lewis RJ, Garcia ML (2003) Therapeutic potential of venom peptides. Nat Rev Drug Discov 2:790–802CrossRefGoogle Scholar
  24. Liu T, Liu Y, Wang Y, Hull M, Schultz PG, Wang F (2014) Rational design of CXCR4 specific antibodies with elongated CDRs. J Am Chem Soc 136:10557–10560CrossRefGoogle Scholar
  25. Macedo JKA, Fox JW, de Souza Castro M (2015) Disintegrins from snake venoms and their applications in cancer research and therapy. Curr Protein Pept Sci 16:532–548CrossRefGoogle Scholar
  26. Mahadevappa R, Ma R, Kwok HF (2017) Venom peptides: improving specificity in cancer therapy. Trends Cancer 3:611–614CrossRefGoogle Scholar
  27. Masuyer G, Schwager SL, Sturrock ED, Isaac RE, Acharya KR (2012) Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Sci Rep 2:717CrossRefGoogle Scholar
  28. Matsui T, Fujimura Y, Titani K (2000) Snake venom proteases affecting hemostasis and thrombosis. Biochim Biophys Acta 1477:146–156CrossRefGoogle Scholar
  29. Murray JK, Qian YX, Liu B, Elliott R, Aral J, Park C, Zhang X, Stenkilsson M, Salyers K, Rose M, Li H, Yu S, Andrews KL, Colombero A, Werner J, Gaida K, Sickmier EA, Miu P, Itano A, McGivern J, Gegg CV, Sullivan JK, Miranda LP (2015) Pharmaceutical optimization of peptide toxins for ion channel targets: potent, selective, and long-lived antagonists of KV1.3. J Med Chem 58:6784–6802CrossRefGoogle Scholar
  30. Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ (2012) Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease? J Neurochem 120(Suppl 1):167–185CrossRefGoogle Scholar
  31. Nielsen CK, Lewis RJ, Alewood D, Drinkwater R, Palant E, Patterson M, Yaksh TL, McCumber D, Smith MT (2005) Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain 118:112–124CrossRefGoogle Scholar
  32. Obata H, Conklin D, Eisenach JC (2005) Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain 113:271–276CrossRefGoogle Scholar
  33. Oršolić N (2012) Bee venom in cancer therapy. Cancer Metastasis Rev 31:173–194CrossRefGoogle Scholar
  34. Ouyang C, Teng C-M, Huang T-F (1990) Characterization of snake venom principles affecting blood coagulation and platelet aggregation. In: Liu CY, Chien S (eds) Fibrinogen, thrombosis, coagulation, and fibrinolysis. Springer, Boston, pp 151–163CrossRefGoogle Scholar
  35. Pal SK, Gomes A, Dasgupta SC, Gomes A (2002) Snake venom as therapeutic agents: from toxin to drug development. Indian J Exp Biol 40:1353–1358PubMedGoogle Scholar
  36. Pertovaara A, Almeida A (2006) Chapter 13 descending inhibitory systems. In: Cervero F, Jensen TS (eds) Handbook of clinical neurology. Elsevier, New York, pp 179–192Google Scholar
  37. Rigo FK, Dalmolin GD, Trevisan G, Tonello R, Silva MA, Rossato MF, Klafke JZ, Cordeiro MDN, Castro Junior CJ, Montijo D, Gomez MV, Ferreira J (2013) Effect of ω-conotoxin MVIIA and Phα1β on paclitaxel-induced acute and chronic pain. Pharmacol Biochem Behav 114–115:16–22CrossRefGoogle Scholar
  38. Rodriguez C, Rollins-Smith L, Ibanez R, Durant-Archibold AA, Gutierrez M (2017) Toxins and pharmacologically active compounds from species of the family Bufonidae (Amphibia, Anura). J Ethnopharmacol 198:235–254CrossRefGoogle Scholar
  39. Sahand ES, Shahla J, Delavar S, Pargol GM, Kamran PB (2016) A new, high yield, rapid, and cost-effective protocol to deprotection of cysteine-rich conopeptide, omega-conotoxin MVIIA. Chem Biol Drug Des 87:687–693CrossRefGoogle Scholar
  40. Samy RP, Stiles BG, Franco OL, Sethi G, Lim LHK (2017) Animal venoms as antimicrobial agents. Biochem Pharmacol 134:127–138CrossRefGoogle Scholar
  41. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, Nannizzi L, Charo IF (1991) Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 266:9359–9362PubMedGoogle Scholar
  42. Sharpe IA, Palant E, Schroeder CI, Kaye DM, Adams DJ, Alewood PF, Lewis RJ (2003) Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship. J Biol Chem 278:40317–40323CrossRefGoogle Scholar
  43. Shen B, Cao Z, Li W, Sabatier JM, Wu Y (2017) Treating autoimmune disorders with venom-derived peptides. Expert Opin Biol Ther 17:1065–1075CrossRefGoogle Scholar
  44. Silva J, Monge-Fuentes V, Gomes F, Lopes K, Anjos L, Campos G, Arenas C, Biolchi A, Gonçalves J, Galante P, Campos L, Mortari M (2015) Pharmacological alternatives for the treatment of neurodegenerative disorders: wasp and bee venoms and their components as new neuroactive tools. Toxins 7:3179CrossRefGoogle Scholar
  45. Tu AT (1996) Overview of snake venom chemistry. In: Singh BR, Tu AT (eds) Natural toxins 2: structure, mechanism of action, and detection. Springer, Boston, pp 37–62CrossRefGoogle Scholar
  46. Vyas VK, Brahmbhatt K, Bhatt H, Parmar U (2013) Therapeutic potential of snake venom in cancer therapy: current perspectives. Asian Pac J Trop Biomed 3:156–162CrossRefGoogle Scholar
  47. Wang X, Guo Z (2015) Anti-gliomas effect of chlorotoxin-conjugated onconase at high dose. Cell Biochem Biophys 73:389–392CrossRefGoogle Scholar
  48. Wang S-Z, Qin Z-H (2018) Anti-inflammatory and immune regulatory actions of Naja naja atra venom. Toxins 10:100CrossRefGoogle Scholar
  49. Wang RE, Wang Y, Zhang Y, Gabrelow C, Zhang Y, Chi V, Fu Q, Luo X, Wang D, Joseph S, Johnson K, Chatterjee AK, Wright TM, Nguyen-Tran VT, Teijaro J, Theofilopoulos AN, Schultz PG, Wang F (2016a) Rational design of a KV1.3 channel-blocking antibody as a selective immunosuppressant. Proc Natl Acad Sci USA 113:11501–11506CrossRefGoogle Scholar
  50. Wang Y, O’Bryant Z, Wang H, Huang Y (2016b) Regulating factors in acid-sensing ion channel 1a function. Neurochem Res 41:631–645CrossRefGoogle Scholar
  51. Yang S, Liu Z, Xiao Y, Li Y, Rong M, Liang S, Zhang Z, Yu H, King GF, Lai R (2012) Chemical punch packed in venoms makes centipedes excellent predators. Mol Cell Proteomics 11:640–650CrossRefGoogle Scholar
  52. Yang S, Xiao Y, Kang D, Liu J, Li Y, Undheim EA, Klint JK, Rong M, Lai R, King GF (2013) Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models. Proc Natl Acad Sci USA 110:17534–17539CrossRefGoogle Scholar
  53. Zeng WZ, Liu DS, Xu TL (2014) Acid-sensing ion channels: trafficking and pathophysiology. Channels (Austin) 8:481–487CrossRefGoogle Scholar
  54. Zhang Y, Wang D, de Lichtervelde L, Sun SB, Smider VV, Schultz PG, Wang F (2013a) Functional antibody CDR3 fusion proteins with enhanced pharmacological properties. Angew Chem Int Ed Engl 52:8295–8298CrossRefGoogle Scholar
  55. Zhang Y, Wang D, Welzel G, Wang Y, Schultz PG, Wang F (2013b) An antibody CDR3-erythropoietin fusion protein. ACS Chem Biol 8:2117–2121CrossRefGoogle Scholar
  56. Zhang Y, Goswami D, Wang D, Wang TS, Sen S, Magliery TJ, Griffin PR, Wang F, Schultz PG (2014) An antibody with a variable-region coiled-coil “knob” domain. Angew Chem Int Ed Engl 53:132–135CrossRefGoogle Scholar
  57. Zhao Y, Cai X, Ye T, Huo J, Liu C, Zhang S, Cao P (2011) Analgesic-antitumor peptide inhibits proliferation and migration of SHG-44 human malignant glioma cells. J Cell Biochem 112:2424–2434CrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Laboratory of Protein and Peptide Drugs, Institute of BiophysicsChinese Academy of SciencesBeijingChina

Personalised recommendations